Newsroom 2007
Attention Business/Financial Editors:
Neurochem to present at JPMorgan Healthcare Conference
LAVAL, QC, Jan. 4 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)
announced today that on Thursday, January 11, 2007, Dr. Francesco Bellini,
Chairman, President and CEO, will present Neurochem's overall strategy and
progress to date at the JPMorgan Healthcare Conference to be held at the
Westin St. Francis Hotel, in San Francisco (CA). The presentation will take
place at 9:00 A.M. PST, in the Colonial Room.
The corporate presentation will be available on the Company's Web site at
http://www.neurochem.com/Investor.htm#Presentation following Dr. Bellini's
speech.
A live audio Web cast of Neurochem's presentation can be accessed at
https://events.jpmorgan.com. A replay of the presentation will begin 24 hours
after the actual presentation time, and will be available until January 18,
2007.
About Neurochem
Neurochem Inc. is focused on the development and commercialization of
innovative therapeutics to address critical unmet medical needs. Eprodisate
(KIACTA(TM); formerly FIBRILLEX(TM)) is currently being developed for the
treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for
marketing approval by the U.S. Food and Drug Administration and European
Medicines Agency. Tramiprosate (ALZHEMED(TM)), for the treatment of
Alzheimer's disease, is currently in Phase III clinical trials in both North
America and Europe and tramiprosate (CEREBRIL(TM)), for the prevention of
Hemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a
Phase IIa clinical trial.
To Contact Neurochem
For additional information on Neurochem and its drug development
programs, please call the North American toll-free number 1-877-680-4500 or
visit our Web Site at www.neurochem.com.
Certain statements contained in this news release, other than statements
of fact that are independently verifiable at the date hereof, may constitute
forward-looking statements. Such statements, based as they are on the current
expectations of management, inherently involve numerous risks and
uncertainties, known and unknown, many of which are beyond Neurochem's
control. Such risks include but are not limited to: the impact of general
economic conditions, general conditions in the pharmaceutical industry,
changes in the regulatory environment in the jurisdictions in which Neurochem
does business, stock market volatility, fluctuations in costs, and changes to
the competitive environment due to consolidation, as well as other risks
disclosed in public filings of Neurochem. Consequently, actual future results
may differ materially from the anticipated results expressed in the
forward-looking statements. The reader should not place undue reliance, if
any, on the forward-looking statements included in this news release. These
statements speak only as of the date made and Neurochem is under no obligation
and disavows any intention to update or revise such statements as a result of
any event, circumstances or otherwise. Please see the Annual Information Form
for further risk factors that might affect the Company and its business.
For further information: Lise Hébert, PhD, Vice President, Corporate
Communications, (450) 680-4570, lhebert@neurochem.com
